Sagimet Biosciences Inc. financial data

Symbol
SGMT on Nasdaq
Location
155 Bovet Rd., Suite 303, San Mateo, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity 3.31 % -70.9%
Return On Equity -42.4 % -79.4%
Return On Assets -40.3 % -76%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 30.7M shares +43.5%
Common Stock, Shares, Outstanding 0 shares -100%
Entity Public Float 102M USD
Weighted Average Number of Shares Outstanding, Basic 32.5M shares +1%
Weighted Average Number of Shares Outstanding, Diluted 32.5M shares +1%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 2M USD
Research and Development Expense 46.5M USD +55.7%
General and Administrative Expense 17.8M USD +12.3%
Operating Income (Loss) -64.3M USD -40.7%
Net Income (Loss) Attributable to Parent -57.7M USD -53.7%
Earnings Per Share, Basic -1 USD/shares -103%
Earnings Per Share, Diluted -1 USD/shares -103%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 32.5M USD -57.8%
Marketable Securities, Current 84.2M USD +11.6%
Cash, Cash Equivalents, and Short-term Investments 126M USD -26.2%
Other Assets, Current 253K USD +150%
Assets, Current 119M USD -24%
Operating Lease, Right-of-Use Asset 115K USD +0.88%
Other Assets, Noncurrent 62K USD
Assets 128M USD -26.5%
Accounts Payable, Current 4.24M USD +268%
Employee-related Liabilities, Current 1.29M USD +29.8%
Accrued Liabilities, Current 4.79M USD +69.5%
Liabilities, Current 9.15M USD
Liabilities 7.18M USD +59.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax 117K USD -73.5%
Retained Earnings (Accumulated Deficit) -337M USD -20.7%
Stockholders' Equity Attributable to Parent 119M USD -30.1%
Liabilities and Equity 128M USD -26.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -14.5M USD -134%
Net Cash Provided by (Used in) Financing Activities 105M USD
Net Cash Provided by (Used in) Investing Activities 3.41M USD +13.8%
Common Stock, Shares Authorized 0 shares -100%
Common Stock, Shares, Issued 0 shares -100%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 32.5M USD -57.8%
Deferred Tax Assets, Valuation Allowance 66.4M USD +20.5%
Deferred Tax Assets, Gross 66.4M USD +20.4%
Operating Lease, Liability 78K USD +20%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -58M USD -56.4%
Lessee, Operating Lease, Liability, to be Paid 80K USD +21.2%
Operating Lease, Liability, Current 115K USD -0.86%
Lessee, Operating Lease, Liability, to be Paid, Year One 80K USD +21.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure +28.6%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2K USD +100%
Deferred Tax Assets, Operating Loss Carryforwards 35M USD +12.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 2.19M USD +22.5%
Additional Paid in Capital 456M USD +1.46%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 16K USD -62.8%
Share-based Payment Arrangement, Expense 6.29M USD +24.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%